Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02054897 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 388
- Enrollment target
NCT02054897: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT02054897 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 388 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02054897, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 388 participants
- Enrollment target
Study Summary
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
Primary Outcome
Change from baseline (week 0) in HbA1c was evaluated after 30 weeks of treatment. Missing data were imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Interventions
- DRUG placebo
- DRUG semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2014-02-03 |
| Est. Completion | 2015-05-08 |
| Phase | Phase 3 |
What the finished NCT02054897 record still lists
NCT02054897 is an interventional study that assigns participants to a tested intervention. The registered 388 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02054897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02054897 about?
NCT02054897 is a clinical study titled "Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes". This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes. (SUSTAIN™ 1-Monotherapy).
What is the current status of trial NCT02054897?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 388 participants. The study started on 2014-02-03. Estimated completion is 2015-05-08.
What interventions are being tested in trial NCT02054897?
The interventions under investigation include: placebo (DRUG), semaglutide (DRUG).
Who is sponsoring clinical trial NCT02054897?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02054897's enrollment target sits among peer trials
388 973rd of 2000 higher than 1,028 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
- NCT05157880 · 388 participants · NA
Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
- NCT05748613 · 388 participants · NA
Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's
- NCT06374277 · 388 participants · NA
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI